1. Home
  2. MDCX vs CGTX Comparison

MDCX vs CGTX Comparison

Compare MDCX & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDCX
  • CGTX
  • Stock Information
  • Founded
  • MDCX 2008
  • CGTX 2007
  • Country
  • MDCX Canada
  • CGTX United States
  • Employees
  • MDCX N/A
  • CGTX N/A
  • Industry
  • MDCX
  • CGTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MDCX
  • CGTX Health Care
  • Exchange
  • MDCX Nasdaq
  • CGTX Nasdaq
  • Market Cap
  • MDCX 33.8M
  • CGTX 30.0M
  • IPO Year
  • MDCX N/A
  • CGTX 2021
  • Fundamental
  • Price
  • MDCX $3.68
  • CGTX $0.59
  • Analyst Decision
  • MDCX Strong Buy
  • CGTX Strong Buy
  • Analyst Count
  • MDCX 1
  • CGTX 6
  • Target Price
  • MDCX $10.00
  • CGTX $8.30
  • AVG Volume (30 Days)
  • MDCX 17.1K
  • CGTX 825.5K
  • Earning Date
  • MDCX 01-01-0001
  • CGTX 03-25-2025
  • Dividend Yield
  • MDCX N/A
  • CGTX N/A
  • EPS Growth
  • MDCX N/A
  • CGTX N/A
  • EPS
  • MDCX N/A
  • CGTX N/A
  • Revenue
  • MDCX N/A
  • CGTX N/A
  • Revenue This Year
  • MDCX N/A
  • CGTX N/A
  • Revenue Next Year
  • MDCX N/A
  • CGTX N/A
  • P/E Ratio
  • MDCX N/A
  • CGTX N/A
  • Revenue Growth
  • MDCX N/A
  • CGTX N/A
  • 52 Week Low
  • MDCX $1.80
  • CGTX $0.34
  • 52 Week High
  • MDCX $3.87
  • CGTX $2.95
  • Technical
  • Relative Strength Index (RSI)
  • MDCX N/A
  • CGTX 39.91
  • Support Level
  • MDCX N/A
  • CGTX $0.57
  • Resistance Level
  • MDCX N/A
  • CGTX $0.68
  • Average True Range (ATR)
  • MDCX 0.00
  • CGTX 0.06
  • MACD
  • MDCX 0.00
  • CGTX -0.02
  • Stochastic Oscillator
  • MDCX 0.00
  • CGTX 7.83

About MDCX Medicus Pharma Ltd. Common Stock

Medicus Pharma Ltd is a clinical-stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: